Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine_ an interim analysis of a randomised controlled phase 3 trial in Russia Auteur/autrice de la publication :Admin Publication publiée :3 février 2021 Post category:COVID 19 Safety-and-efficacy-of-an-rAd26-and-rAd5-vector-based-heterologous-prime-boost-COVID-19-vaccine_-an-interim-analysis-of-a-randomised-controlled-phase-3-trial-in-RussiaTélécharger Vous devriez également aimer Virology, transmission, and pathogenesis of SARS-CoV-2 14 décembre 2020 Comparison of Clinical and Epidemiologic Characteristics of Young 10 février 2021 Immune response during lactation after anti-SARS-CoV2 mRNA vaccine 22 mars 2021